| University of Cambridge - MRC LMB | |
|---|---|
| Institution logo (if available) | |
| Location | Cambridge, UK |
| Type | Research Institute |
| Website | https://www.mrc-lmb.cam.ac.uk/ |
| Focus Areas | Tau, alpha-synuclein, Protein aggregation |
| Departments | MRC Laboratory of Molecular Biology |
University Of Cambridge Mrc Lmb is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
University of Cambridge - MRC LMB is a research institute located in Cambridge, UK. The institution is recognized for its contributions to neurodegenerative disease research, with focus areas including [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--, [alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--, Protein aggregation.
University of Cambridge - MRC LMB hosts 1 researchers tracked in the NeuroWiki database and maintains 1 department dedicated to neuroscience research. The institution's research programs span Tau, alpha-synuclein, Protein aggregation, contributing to both basic science understanding and translational approaches for neurodegenerative conditions.
Through its MRC Laboratory of Molecular Biology, University of Cambridge - MRC LMB supports multidisciplinary investigation into the mechanisms, diagnosis, and treatment of neurodegenerative diseases. The institution's researchers have published extensively on topics including Tau, alpha-synuclein, Protein aggregation and continue to advance the field through clinical trials, biomarker development, and fundamental neuroscience research.
Program-level enrichment pending curation for this institution.
Lab-level enrichment pending curation for this institution.
| Researcher | H-index | Focus Areas |
|---|---|---|
| [Michel Goedert[/researchers/[michael-goedert[/researchers/[michael-goedert[/researchers/[michael-goedert--TEMP--/researchers)--FIX-- | 250 | Alzheimer's Disease, Parkinson's Disease, FTD |
The neurodegenerative disease portfolio at University of Cambridge - MRC LMB supports a continuum from mechanism-focused laboratory research to patient-oriented studies. Institutional investigators contribute to biomarker qualification, patient stratification frameworks, and trial endpoint development that can accelerate therapeutic evaluation.
By combining longitudinal cohorts with mechanistic expertise, the institution helps connect observations from [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/diseases pages to hypotheses represented across [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms. This translational model helps prioritize therapies with stronger biological rationale and clearer paths to testing.
The institution's programs also contribute to workforce development through training programs, collaborative grants, and open-science dissemination. These activities strengthen cross-site reproducibility and enable tighter integration between basic neuroscience discoveries and clinical decision-making.
The study of University Of Cambridge Mrc Lmb has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.